drugset / Trial / NCT07519395

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

NCT07519395

Phase 2 Recruiting 420 enrolled GlaxoSmithKline
RandomizedSequentialTriple-blindTreatment

Summary

This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.

Timeline

Start
2026-04-08
Primary completion
2027-03-09
Completion
2027-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Camlipixant Small molecule